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Methylmercury (MeHg) is an environmental
organometal that acts as a neurotoxicant in
humans, nonhuman primates, rodents, and
other mammals, and the developing nervous
system is an important target of its toxicity
(Burbacher et al. 1990; Clarkson 1987; NRC
2000). Epidemiologic studies conducted
worldwide since the 1950s have associated
MeHg exposure with a range of effects rang-
ing from mild behavioral alterations to death
(reviewed in NRC 2000). Human exposure is
associated primarily with consumption of
fish and seafood containing trophically
accumulated MeHg.
The effects of in utero MeHg exposure
differ from effects observed after childhood or
adult exposure (Harada 1968a, 1968b;
Takeuchi 1968, 1977; Tokuomi 1968).
Prenatal exposure to MeHg appears to result
in a widespread pattern of adverse effects on
brain development and organization com-
pared with the relatively restricted damage
observed when exposure occurs later in life
(Choi et al. 1978; Hamada et al. 1993;
Matsumoto et al. 1965; Takeuchi 1968). The
widespread nature of damage that occurs in
cases of fetal disease in both animal models
and humans is characterized by a) decreased
cellular abundance (hypoplasia) and micro-
cephaly in which brain weight can be reduced
by as much as one-half to two-thirds or nor-
mal; b) altered cellular migration, which
results in dysplasia and altered cortical cytoar-
chitecture; and c) gliosis (Choi 1986, 1989;
Choi et al. 1978; Eto et al. 1992; Geelen et
al. 1990; Matsumoto et al. 1965; Mottet
1974, 1989; Mottet and Ferm 1983;
Takeuchi 1968, 1977).
The fetus appears to be more sensitive to
the toxic effects of MeHg relative to the
mother, and adverse neurodevelopmental
effects have been reported in the offspring of
women showing little or no overt toxicity
(Clarkson et al. 1985; Harada 1977, 1978;
Marsh 1987; Marsh et al. 1987). The mecha-
nisms underlying the differences in sensitivity
are unclear but can be attributed at least in
part to interruption of the highly regulated
processes associated with fetal growth and
development that are not occurring in the
mother. In particular, normal central nervous
system (CNS) development requires a highly
synchronized progression of events involving
rapid and coordinated cell division, migra-
tion, differentiation, and selective cell loss
(Herschkowitz 1988). Agents that interfere
with any of these processes may interfere with
downstream events (Faustman et al. 1996),
and the developing CNS may not be able to
compensate for damage that occurs during
particular stages in development (Bayer 1989;
Rice and Barone 2000). This limited com-
pensatory capacity likely underlies not only
the relatively higher sensitivity of the fetus to
MeHg exposure relative to the adult but also
differences in neuropathology.
The biochemical rationale for MeHg-
induced cellular toxicity is incompletely
understood. As a general rule, the biochemi-
cal toxicity of MeHg and other mercurials is
attributed to its extremely high affinity for
protein sulfhydryl groups (Hughes 1957).
Because of the common role for disulfide
bond formation in stabilizing and maintain-
ing protein tertiary structure, nonspecific
changes in protein structure or enzyme func-
tion may occur following interaction between
MeHg and cysteine sulfur groups. The non-
speciﬁc nature of interaction between MeHg
and cellular macromolecules makes it unlikely
that there is a single underlying event respon-
sible for the myriad effects observed upon
MeHg exposure.
Several lines of evidence support the
hypothesis that the reduced cell number
observed upon MeHg exposure in vivo
derives from inhibition of cell proliferation,
primarily in mitosis (M), rather than cell
necrosis. First, MeHg-induced inhibition of
germinal cell proliferation demonstrates the
capacity of MeHg to reduce the number of
progenitor cells and indicates lasting effects
from inhibition of cell proliferation during
early CNS development (Choi 1991; Sager
et al. 1984). 
Second, histologic evidence has demon-
strated reduced brain size and weight (micro-
cephaly) and evidence of impaired cell cycle
transition and mitotic inhibition, in the
absence of focal necrosis (Choi 1989; Howard
This article is part of the monograph Molecular
Mechanisms of Metal Toxicity and Carcinogenicity.
Address correspondence to E.M. Faustman, Dept.
of Environmental Health, 4225 Roosevelt Way NE,
Suite 100, University of Washington, Seattle, WA
98105 USA. Telephone: (206) 685-2269. Fax: (206)
685-4696. E-mail: faustman@u.washington.edu
This work was supported by National Institute of
Environmental Health Sciences, National Institutes
of Health grants P01-ES09601, P30-ES07033, R01-
ES10613-01, and 2T-32ES0-7032, and U.S.
Environmental Protection Agency grants R-826886-
01-0 and R-825358-01-2. We express appreciation
to A.J. Fornace Jr. and W. Harper for technical con-
tributions, and to S.W. Hong for assistance in vari-
ous aspects of this project. 
Received 21 March 2002; accepted 4 June 2002.
Metals Toxicity
Methylmercury (MeHg) has been an environmental concern to public health and regulatory agen-
cies for over 50 years because of its toxicity to the human nervous system. Its association with ner-
vous system toxicity in adults and infants near Minamata Bay, Japan, in the 1950s initiated
environmental health research inquiries that continue to this day. Observations of greater neuro-
toxicity with gestational compared with adult exposure suggest a unique susceptibility of the
developing nervous system to MeHg. Despite extensive research conducted over the last half cen-
tury, determination of deﬁnitive molecular mechanisms underlying the observed neurotoxic effects
of MeHg have not been identiﬁed. This paper summarizes results of a series of experiments con-
ducted to examine the effects of MeHg on neuroepithelial cell proliferation, a hypothesized mode
of action for its selective effects on neurogenesis. Observed effects of MeHg on cell cycle entry and
progression were associated with alterations in a variety of cell cycle regulatory molecules, includ-
ing p21 signaling pathways. We place these studies in the context of other cellular responses
involved in signal transduction, including oxidative stress, altered protein phosphorylation, and
altered intracellular calcium homeostasis. Although existing information suggests that no single
mechanism underlies the diverse array of effects associated with MeHg-induced developmental
neurotoxicity, we demonstrate characteristic effects of MeHg on cell signaling that contribute to
observed effects on cell proliferation. Experimentally derived cell cycle kinetic and cytotoxicity
data allowed development of a biologically based dose–response model of MeHg-induced alter-
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testing and for use in assessing risks from environmental exposures. Key words: cell cycle, chil-
dren’s health, developmental toxicology, methylmercury, neurogenesis, proliferation. Environ
Health Perspect 110(suppl 5):859–864 (2002).
http://ehpnet1.niehs.nih.gov/docs/2002/suppl-5/859-864faustman/abstract.html
Investigations of Methylmercury-Induced Alterations in Neurogenesis
Elaine M. Faustman,1,2 Rafael A. Ponce,1,2 Ying C. Ou,3 Ma. Aileen C. Mendoza,4 Thomas Lewandowski,5
and Terrance Kavanagh1, 2 
1Department of Environmental Health, University of Washington, Seattle, Washington, USA; 2Center for Child Environmental Health
Risks Research, Seattle, Washington, USA; 3Otsuka Maryland Research Institute, Otsuka Pharmaceutical Co., Rockville, Maryland, USA;
4Tetra Tech EM Inc., San Francisco, California, USA; 5Gradient Corporation, Mercer Island, Washington, USA860 VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 • Environmental Health Perspectives
and Mottet 1986; Matsumoto et al. 1965;
Rodier et al. 1984). These ﬁndings suggest that
impaired cell proliferation rather than necrotic
damage underlies the observed microcephaly.
Third, examination of the cell cycle
effects elicited by MeHg demonstrates
mitotic inhibition both in vivo and in vitro
(Miura et al. 1978; Ponce et al. 1994; Rodier
et al. 1984; Sager 1988).
In this article we summarize results of a
series of experiments conducted to character-
ize the biochemical, cellular, and molecular
effects of MeHg on neuroepithelial cell prolif-
eration. Observed effects demonstrate that
MeHg can alter gene expression, intracellular
redox balance, and intracellular calcium
(Ca2+)i homeostasis at levels of exposure also
associated with altered cell cycle entry and
progression. Results of these experiments
were compiled in a biologically based
dose–response model of MeHg-induced
neurodevelopmental toxicity that is used to
explore the role of alternative pathways on
overall toxicity and generate hypotheses for
further testing.
Materials and Methods
Primary rat embryo CNS cells and in vivo
assessments were used to study the develop-
mental toxicity of MeHg (Alfa Aesar, Ward
Hill, MA, USA). The use of the in vitro cell
culture system allowed well-controlled evalua-
tion of the effects of MeHg on cell viability,
differentiation, and cell cycling (Ou et al.
1999a; Ponce et al. 1994). As with other
regions of the developing CNS, midbrain
neuroepithelial cell proliferation appears to be
sensitive to the effects of in utero MeHg expo-
sure (Rodier et al. 1984). The primary neu-
roepithelial cell cultures derived from the
gestation day 12 rat midbrain during the
rapid phase of midbrain neuronal prolifera-
tion yield a mixed cell culture enriched in
neuroblasts that undergo terminal differentia-
tion without the addition of exogenous
growth factors. As a result, these cells are an
excellent model for investigating various
aspects of normal brain development, includ-
ing mechanisms of cell cycle regulation and
terminal differentiation (Whittaker et al.
1993). Evaluation of these cultures demon-
strates similarity in protein expression with
the in vivo CNS midbrain (Whittaker et al.
1993). Because these cultures use primary
cells rather than transformed or immortalized
cell lines (e.g., neuroblastoma and glioma cell
cultures), they serve as useful models for the
evaluation of the mechanisms and effects of
MeHg on developing CNS.
Methods used to investigate alterations
in mRNA and protein levels of cell cycle
regulatory genes [e.g., p21, growth arrest
and DNA damage (GADD)45, GADD153]
in developmentally exposed mice have been
previously described (Ou et al. 1997,
1999a). Briefly, these experiments involved
prenatal MeHg exposure through drinking
water (0, 3, 10 ppm) and harvest of fetal and
adult neuronal tissues. Changes in gene
expression and protein levels, examined by
Northern blotting, Western blotting, and
immunoprecipitation, were correlated with
tissue MeHg content analysis.
The role of p21 in cell cycle alterations
induced by MeHg was further examined using
primary mouse embryonic ﬁbroblasts (MEFs)
of different p21 genotypes (wild type, het-
erozygous, and null) (Mendoza et al. 2002).
Cells were harvested and isolated at day 14 of
gestation and treated at passage 4–6 with
either 0, 2, 4, or 6 mM MeHg or 50 nM
colchicine (Sigma Chemicals, St. Louis, MO,
USA) for 24 hr, with subsequent examination
of cell cycle alterations by ﬂow cytometry, as
described below.
Investigations into the effects of MeHg on
the cell cycle were performed using single- and
dual-parameter flow cytometry. Single-
parameter flow cytometric analysis of
4,6-diamidino-2-phenylindole (DAPI)-stained
CNS cultures incubated with MeHg was used
to quantify changes in DNA content as a
means for examining changes in cell cycle
phase distribution. Dual-parameter ﬂow cyto-
metric analysis of 5-bromo-2´-deoxyuridine
(BrdU)-labeled cells, using two DNA fluo-
rochromes, Hoechst 33258 and ethidium bro-
mide (EB) was used to evaluate the progression
of the primary CNS cells through the cell cycle
(Rabinovitch et al. 1988). This method works
well with asynchronous cell populations such
as the primary cells used in experiments sum-
marized here. DAPI, BrdU, Hoeschst 33258,
and EB were purchased from Sigma.
The effects of MeHg on intracellular glu-
tathione (GSH) and γ -glutamyl cysteine syn-
thetase (γ -GCS) regulation in rat midbrain
neuroepithelial cells was also examined (Ou
et al. 1999b). These experiments used
N-acetyl-L-cysteine and L-buthionine-(S,R)-
sulfoximine (BSO) as control agents to
induce and deplete, respectively, intracellular
GSH. Relative changes in GSH content,
γ -GCS activity, GSH levels, γ -GCS-heavy
chain (γ -GCS–HC) mRNA expression, and
γ -GCS-HC protein content were quantified
over time in response to MeHg or control
article treatment (Ou et al. 1999b).
Adherent cell analysis on the ACAS
Ultima scanning laser cytometer (Meridian
Instruments, Okemos, MI, USA) was used to
examine the acute (17-min) effect of MeHg on
indo-1 ﬂuorescence as a measure of changes in
intracellular calcium [Ca]i. This instrument
used a water-cooled Coherent Enterprise
argon-ion laser (Coherent, Palo Alto, CA,
USA) with excitation at 351–364 nm.
Emission was split by a 445-nm longpass
dichroic and gathered independently by two
photomultiplier tubes using either a 405/45-
nm bandpass ﬁlter or a 530/30-nm bandpass
filter. Ultraviolet (UV) laser output was
maintained at 30 mW. Images were obtained
through a 100× , 1.3 n.a., UV-corrected oil-
immersion objective mounted on an
Olympus IM-T-2 microscope. A determina-
tion of basal [Ca2+]i was performed on con-
trol cells (cells unexposed to MeHg)
according to Grynkiewicz et al. (1985).
Triplicate experiments were conducted to
investigate the acute effects of MeHg exposure
(17 min) on basal indo-1 ﬂuorescence. Cells
were incubated in 1 mL indo-1/AM solution
for 45 min and then rinsed twice with either
phosphate-buffered saline containing calcium
and magnesium (Ca–PBS) or 0Ca–PBS (cal-
cium- and magnesium-free PBS + 5 mM
EGTA) (Gibco Life Technologies Inc., Grand
Island, NY, USA). Cells were then incubated
either in Ca–PBS or 0Ca–PBS and placed in a
heated chamber (37°C) on the inverted micro-
scope stage. After obtaining a 3-min baseline
from a random ﬁeld, MeHg was added to the
chamber (0–10 µM), and the indo-1 ﬂuores-
cence was monitored for another 17 min.
Scans were performed at 1-min intervals.
Results are reported as percent change in the
ﬂuorescence ratio relative to the average basal
fluorescence ratio without conversion to
[Ca2+]i, because of concerns raised by Hare et
al. (1993) and Denny et al. (1993) that
MeHg may be mobilizing divalent cations
other than Ca2+. Spectroﬂuorometric analysis
of the indo-1 fluorescence spectrum showed
no interaction between MeHg and indo-1. To
investigate whether the addition of EGTA
(Sigma) affected basal [Ca2+]i, indo-1–loaded
CNS cells were incubated in 0Ca-PBS and
placed in a heated chamber (37°C) on the
inverted microscope stage. After obtaining a
3-min baseline, EGTA (5 mM; Sigma) was
added to the buffer, and indo-1 ﬂuorescence
was monitored for an additional 17 min.
Results
In vitro MeHg exposure resulted in primary
neuroepithelial cell death in a time- and con-
centration-dependent manner (Ponce et al.
1994). For example, a 50% reduction in the
number of live cells was observed following
continuous exposure to approximately 2 µM
MeHg for 24 hr or to 0.25 µM for 120 hr.
This reduction in live cell number reflected
both cell death and reduced cell production
because of cell cycle inhibition.
Flow cytometric cell cycle kinetic analysis
of primary rat midbrain neuroepithelial cells
was conducted upon exposure to MeHg or
colchicine (Ponce et al. 1994). After 12 hr of
MeHg exposure, a concentration-dependent
increase in the number of cells in the DNA
synthesis phase of the cell cycle (S phase) was
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seen by DAPI staining and DNA content-
based ﬂow cytometry, and a dose-dependent
increase in the number of cells in the gap 2
phase of the cell cycle (G2)/M was observed
after 24 hr. For example, at 30 hr of incuba-
tion, 2 and 4 µM MeHg signiﬁcantly increased
the proportion of cells in G2/M when com-
pared with control cells (215 ± 12% and 266 ±
66%, respectively). These investigations pro-
vided evidence that MeHg led to a time-
dependent inhibition in S-phase and G2/M in
primary CNS cells. Mitotic inhibition was evi-
dent by BrdU-Hoechst bivariate ﬂow cytomet-
ric analysis at 24-hr incubation in the presence
of either colchicine or MeHg (Ponce et al.
1994). Examination of the dual parameter
cytograms demonstrated that cycling cells
appeared more sensitive to the cytotoxic effects
of MeHg than noncycling cells.
An evaluation of the number of cells able
to successfully complete one round of cell divi-
sion demonstrated an inhibition of cell cycle
transition following MeHg exposure at all time
points and at all tested concentrations (Figure
1, Ponce et al. 1994). Following 48 hr of incu-
bation, 57 ± 6% of control cells had progressed
into a new gap 1 (G1)-phase, whereas cells
exposed to 1, 2, or 4 µM MeHg had only 40 ±
4%, 7 ± 2% (p ≤ 0.05), or 2 ± 1% (p ≤ 0.05)
progression into a new G0/G1-phase. The cell
cycle effects observed upon exposure to MeHg
demonstrated concentration-dependent rela-
tionships: a) inhibition of cell cycle progression
(1 µM MeHg); b) accumulation of cells in
G2/M (2 µM MeHg); and c) cessation of all
cycling activity (4 µM MeHg). Because the
cells used in these investigations were derived
from day 12 fetal rat midbrain, the results
reported here support the hypothesis that
MeHg can inhibit cell cycling during the rapid
phase of CNS cell proliferation.
The effects of MeHg on the expression of
a number of cell cycle regulatory genes in the
primary rat midbrain neuroepithelial cell cul-
ture were examined, particularly genes known
to be involved in the cell cycle control and
growth arrest, including GADD, p53, and
p21 genes. We began by evaluating the con-
stitutive expression level of GADD genes
(GADD45 and GADD153) during cell prolif-
eration and commitment to differentiation.
The Gadd genes are involved in growth arrest
in response to stress and DNA damage and
act at the G1/S checkpoint where we have
observed cell cycle inhibition following
MeHg exposure. To evaluate the effect of
MeHg on the expression of GADD45 and
GADD153, total RNA was isolated from cells
treated with MeHg (0–2 µM, 24 hr). A con-
centration-related increase in the amount of
p21, GADD45, and GADD153 expression in
the MeHg-exposed cells compared with the
untreated cells was observed. A summary of
the induction of GADD45 and GADD153
in vivo and in vitro is presented in Table 1.
(Included in Table 1 are expression data on
γ -GCS, a gene involved in GSH synthesis
implicated in response to oxidative stress.)
Differences in the induction proﬁles of these
two GADD genes have been observed (Zhan
et al. 1994). However, to our knowledge, this
was the first evaluation of the effects of
MeHg on these genes. Because peak induc-
tion of GADD45 has been reported to be
maximal approximately 4 hr after exposure to
an inducer, our measurement of GADD45
expression at 24 hr postexposure may have
underestimated peak induction (Fornace
et al. 1989; Zhan et al. 1994).
Using MEFs from normal, heterozygous,
and null for p21, we examined the effects of
MeHg on cell cycle progression. We observed
no apparent effect of p21 status on cell death
or cell cycle phase distribution upon exposure
to MeHg, although cells of all genotypes
accumulated cells in G2/M (Mendoza et al.
2002). Bivariate BrdU/Hoechst flow cyto-
metric analyses demonstrated that p21 par-
tially regulated MeHg-induced inhibition of
cell cycle progression, wherein a higher frac-
tion of p21(– /–) cells successfully completed
one cell cycle round compared with both
p21(+/+) and p21(+/–) cells (Figure 2). These
results suggested a complex relationship
between p21 and other proteins involved in
cell cycle regulation after exposure to MeHg,
and suggested that a partial loss of the G1 and
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Table 1. Change in gene expression (mRNA levels) in control and treated rodent CNS cells in vitro and in vivo for four
genes: GADD45, GADD153, γ -GCS–HC, and p21.a
GADD45 GADD153 γ -GCS–HC p21
Normal development
In vitro, embroyonic CNS 1.8 × ↓ BD ND 1.7 × ↓
MeHg exposed
In vivo, adult CNS 1.6 × ↑ 6.2 × 1.1 × ↑ 1.5 × ↑ 5.6 × ↑ *
In vitro, embroyonic 6.2 × ↑ * 4.7 × ↑ * 1.2 × ↑ 2 × ↑ *
Abbreviations: ND, not determined; BD, below detectable levels; ↑ , induction; ↓ , inhibition/repression. 
aThe greatest induction was observed in vitro for GADD45 and GADD153 and for p21 in vivo following 4 weeks of MeHg
exposure. GADD45 and p21 expression decreased with CNS cell differentiation in vitro. Northern blots were carried out
using brain tissue from adult mice chronically exposed to low levels of MeHg (10 ppm, 4 weeks) and from CNS cells
exposed to 2 µM MeHg in vitro for 24 hr. Northern blots were also carried out using CNS cells to look for changes during
normal neuronal differentiation. Arrows represent fold change after normalization to 18 S and control conditions. Table
adapted from Ou et al. (1997, 1999a). *Signiﬁcantly different from the expression levels of untreated controls (p < 0.05).
Values shown are the means from at least three independent experiments.
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Figure 1. Proportion of CNS cells successfully com-
pleting one round of cell dividion and reaching sec-
ond-round G1 and (G1
2) following 24-, 30-, 36-, and
48-hr incubation with BrdU and MeHg. MeHg expo-
sure results in a concentration-dependent decrease
in the ability of primary CNS cells to transition
through the cell cycle, as demonstrated by BrdU-
Hoechst flow cytometry. With higher exposures
(>4 µM), MeHg blocks cell cycle transition. Cultures
exposed to 2 and 4 µM MeHg showed a signiﬁcant
decline in the percentage of cells reaching a new
G0/G1 following a successful M relative to controls
at all time points (p ≤ 0.05). Data from Ponce et al.
(1994), with permission of Academic Press.
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Figure 2. Effect of MeHg on cell cycle progression of MEFs of different p21 genotypes. Asynchronous cells
(passage 4–6) were treated with 0, 2, 4, and 6 µM MeHg and labeled with BrdU for (A) 24 hr and (B) 48 hr.
Cells were harvested and then stained with Hoechst 33258 and EB. The fraction of cells (n ≥ 3) reaching
second-round G1 (G1
2) after 24 and 48 hr of MeHg treatment is shown (mean ± SE). Statistically signiﬁcant
differences (p ≤ 0.05) relative to control untreated cells were observed across both MeHg exposure groups
(†) and p21 genotype status (*). Data from Mendoza et al. (2002), with permission of Academic Press.G2/M checkpoints in p21(–/–) cells con-
tributed to the higher rate of progression of
these cells through the cell cycle and out of
mitotic inhibition. The lack of a complete
abrogation of the G1 or G2 checkpoints in
the MeHg response of p21(–/–) cells may be
attributed to redundant cell cycle regulatory
pathways (Shackelford et al. 1999).
We also examined the effects of MeHg on
regulation of Ca2+
i homeostasis and GSH as
potential biochemical bases for the altered
signal transduction and cell cycling observed
in the primary rat midbrain neuroepithelial
cells. The role of GSH in MeHg-mediated
cell cycle alterations was examined in our lab-
oratory with the use of GSH-modulating
agents. We observed that GSH depletion by
BSO did not significantly alter MeHg-
induced cytotoxicity in embryonic CNS cells
(Ou et al. 1999b). In contrast, acute exposure
of primary neuroepithelial cells to MeHg
caused an immediate increase in the indo-1
ﬂuorescence ratio, demonstrating an increase
in free [Ca2+
i ] (and possibly other divalent
cations) at MeHg concentrations observed to
affect cell cycling (Figure 3). The elevation in
the basal fluorescence ratio was a strong
function of both the MeHg exposure concen-
tration and the presence of extracellular cal-
cium (Ca2+
e ). Cells exposed to MeHg (1, 2, 4
µM) in the presence of Ca2+
e demonstrated an
increase in indo-1 ﬂuorescence ratio that rose
consistently over the 17 min of observation
(Figure 3). The ﬂuorescence ratio for cultures
exposed to MeHg in the absence of Ca2+
e
demonstrated a markedly lower percentage
change above baseline when compared with
cultures exposed to MeHg in the presence of
Ca2+
e (Figure 3). In the absence of Ca2+
e , a lag
of several minutes was observed before the
ﬂuorescence ratio increased following MeHg
exposure. These results demonstrate that as
the MeHg exposure concentration increased,
the time to intracellular divalent cation mobi-
lization decreased, and the relative contribu-
tion of intracellular divalent cations to the
total indo-1 response increased.
The dose–response information on cell
cycle transition rates, cell viability and differen-
tiation in primary rat midbrain neuroepithelial
cells exposed in vitro was used to develop a
biologically based dose–response model of
MeHg-mediated developmental neurotoxicity
(Leroux et al. 1996). This model incorporates
MeHg-dependent rates to estimate the num-
ber of cells in the fetal midbrain over time
based on transition probabilities for cell
growth, death, and transformation (Figure 4).
This model views development as a process
involving replication of uncommitted cells
(e.g., neuroepithelial cells), differentiation of
uncommitted cells to cells committed to differ-
entiation (e.g., neuronal cells), and cell death,
wherein each of these transitional processes
occurs with a given probability. Transition
probabilities were modeled as Poisson
processes. Kolmogorov forward equations were
used to estimate the mean and variance of the
number of cells in each of the possible states at
any given time. In this way, the probability of
malformation could be predicted as a function
of the number of normal, committed cells by a
given time point (Leroux et al. 1996).
Discussion
Results from experiments summarized here
suggest that the effects of MeHg on cell cycle
alterations likely underlie the neuronal
hypoplasia observed after gestational exposure
and the enhanced susceptibility of the fetus to
MeHg exposure relative to that of the adult.
Moreover, these experiments suggest a multi-
factorial relationship between exposure and
effect involving both timing and degree of
exposure, genetic makeup, and other factors.
Biochemically, the effects of MeHg on GSH
may not be sufﬁcient to explain the observed
effects of MeHg on cell cycle progression (Ou
et al. 1999b). In contrast, we have observed
strong effects of MeHg on intracellular diva-
lent cation regulation, presumably associated
with changes in Ca2+
i , and support a role for
the loss of Ca2+
i homeostasis in the cell cycle
alterations observed in the primary CNS cell
cultures after MeHg exposure. MeHg inter-
feres with the maintenance of normal Ca2+
i in
multiple ways (Atchison and Hare 1994), and
immature neurons may be particularly suscep-
tible to MeHg-mediated alterations in Ca2+
i
(Mundy and Freudenrich 2000). This interfer-
ence reflects the myriad pathways through
which cells regulate Ca2+
i. Results from experi-
ments described here support a model wherein
MeHg exposure led to a sustained elevation in
[Ca2+]i through alterations in both the plasma
membrane permeability toward Ca2+
e (or
which required the presence of Ca2+
e) and
through mobilization of Ca2+
istores. It is likely
that the sustained elevation of [Ca2+]i influ-
ences multiple processes and has a wide range
of outcomes. Among these processes are a) the
activation of cytolytic, Ca2+-dependent
enzymes such as DNases, proteases and lipases;
b) the alteration of Ca2+-dependent protein
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Figure 4. Neurodevelopmental risk model incorporating a toxicokinetic exposure model and a biologically
based dose–response model for MeHg-induced neurodevelopmental toxicity. Figure adapted from
Faustman et al. (1999).
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Figure 3. Effect of MeHg exposure on the 405 nm/530 nm ﬂuorescence ratio of indo-1 over time in primary
rat neuroepithelial cells following in vitro MeHg exposure. Data were obtained from cells exposed to
MeHg both in the presence (Ca–PBS) and absence (0CA–PBS) of Ca2+
e. Data are presented as mean ± SE
(n = 3) change in Indo-1 ﬂuorescence ratio relative to basal. Cell death was negligible over the exposure
duration. No statistical analysis was performed on these data.kinase function; and c) the dysfunction of
other Ca2+-dependent proteins.
Microtubule polymerization is sensitive to
elevated [Ca2+]i, and the phosphorylation of
microtubule-associated proteins are, in some
instances, under the control of Ca2+-depen-
dent protein kinases. Thus, MeHg-induced
alterations in [Ca2+]i may affect microtubule
dynamics independent of direct interactions
of MeHg on microtubule polymerization
(Nicotera et al. 1992; Onfelt 1986) and thus
alter neuronal migration and the formation of
the mitotic spindle. Ca2+ also plays a central
role in cell cycle regulation independent of its
effects on microtubule polymerization
(Berridge 1995). Thus, the appearance of
mitotic figures and neuronal ectopia,
described in humans and animals exposed to
MeHg in utero, may have as a common
underlying cause the loss of Ca2+
i regulation.
The effects of altered Ca2+
i can be directly
associated with altered cell cycle regulation at
the level of the mRNA expression and protein
production/degradation. MeHg-induced
changes in gene expression have been
observed at low levels of exposure in other
systems. For example, marked alterations in
gene expression have been observed in neuro-
blastoma and glioma cells exposed in vitro to
0.05–0.2 µM MeHg for 6–8 weeks
(Ramanujam and Prasad 1979). In adult rat
nervous system (both central and peripheral),
the alterations in expression of 120 genes on
2-dimensional gels, measured as protein level,
were not uniform following in vivo exposure
(10 mg/kg) but changed as a function of both
protein species and period of exposure
(Omata et al. 1991). Because a general effect
on protein synthesis would result in a uni-
form decline in protein level over time, it was
proposed that differential effects at the
mRNA level were occurring (e.g. DNA tran-
scription, mRNA processing, or mRNA alter-
ations by MeHg). However, because the
cellular content of mRNA and protein is
established by a balance between synthesis
and degradation, impaired degradation by
MeHg in these studies cannot be excluded as
a possible underlying mechanism.
Our experiments have shown that MeHg
increases the intracellular mRNA and protein
content of key cell cycle regulatory molecules
under exposure conditions associated with
impaired cell proliferation. p21 (Waf1, Cip1)
is a negative regulator of several cyclin-depen-
dent kinases. By inhibiting the activity of G1
cyclin-dependent kinases, p21 is believed to
inhibit cell cycle transition at the G1-S margin
by blocking retinoblastoma protein phospho-
rylation (Harper et al. 1993). In addition to its
role in the G1 transition, p21 also inhibits
DNA replication by suppressing the ability of
proliferating cell nuclear antigen (PCNA) to
activate DNA polymerase d (Waga et al.
1994). Although p21 appears to be the most
pleiotropic mediator of p53-dependent cell
cycle arrest, both p21 and p53 may act inde-
pendently of the other. For example, p21 is
not required for p53-dependent apoptosis
(Brugarolas et al. 1995), and p21 may act
independently of p53 in cell senescence and in
cell cycle withdrawal upon terminal differenti-
ation (Parker et al. 1995). p21 is activated after
oxidative stress (Russo et al. 1995), and as with
p53, p21 is also a substrate for ubiquitin-medi-
ated protein degradation (Maki and Howley
1997). In addition to their critical role in the
G1-S transition, p53 and p21 may be involved
in G2-M transition control. For example, ele-
vation of p53 protein can arrest cells not only
in G1 but also at G2/M (Guillouf et al. 1995).
In cells lacking p21, the uncoupling of S- and
M-phase transition via a G2 checkpoint by
exposure to anticancer drugs results in many
grossly deformed polyploid nuclei (Waldman
et al. 1996). As with p21, the role of p53 and
other factors on regulated cell cycle checkpoint
control following MeHg exposure can be
investigated using transgenic systems (Caelles
et al. 1994; Schreiber et al. 1999; Shaulian and
Karin 2001).
GADD45 and GADD153 (Chop 10) are
members of a family of GADD genes
(Fornace et al. 1989) that were originally
identified from subtractive hybridization
experiments performed with cells exposed to
UV radiation or the mutagen methyl
methanesulfonate (Fornace et al. 1988). The
expression of GADD45 and GADD153 is
induced by DNA-damaging agents, serum
deprivation, and oxidative stress (Chen et al.
1992). Both are nuclear proteins implicated
in controlling the G1-S transition. GADD45
is activated by p53 and competes with p21 for
binding to PCNA (El-Deiry et al. 1993). In
the ML-1 human myeloid leukemia cell line,
overexpression of GADD45 results in growth
inhibition, as evidenced by a delayed S-phase
entry (Smith et al. 1994). GADD153 acts as a
dominant-negative inhibitor of other C/EBP
transcription factors and is induced upon dif-
ferentiation of ﬁbroblasts to adipocytes (Ron
and Habener 1992). The structure of
GADD153 is similar to other members of the
C/EBP family of transcription factors that
contain a leucine zipper dimerization domain
and a basic DNA-binding domain (Ron and
Habener 1992). Unlike other members of the
C/EBP family, GADD153 works at or
around the G1-S checkpoint, as microinjec-
tion of GADD153 protein into synchronized
NIH-3T3 cells can arrest the cell cycle at the
G1-S boundary (Barone et al. 1994).
The intracellular content of these cell
cycle regulatory molecules is controlled by
both their selective synthesis and degradation.
For example, inhibition of proteasome activ-
ity leads to an increase in p21 protein levels
(Adams et al. 1999), and inhibition of E1
enzyme function results in increased p53
abundance (Laroia et al. 1999). There is rea-
sonable evidence to suggest a role for MeHg
in interfering with regulated protein degrada-
tion leading to altered cell proliferation.
Specifically, because the thiol proteinases,
including the ubiquitin/proteasomes and cal-
pains, absolutely require the activity of a con-
served cysteine for normal function, it is
plausible to propose that MeHg may directly
interfere with their activity. The activities of
the calpains and ubiquitin/proteasomes are
regulated by intracellular redox status and free
Ca2+
i (Berleth and Pickart 1996; Hochstrasser
1996), both of which are sensitive to MeHg
exposure (Atchison and Hare 1994; Saraﬁan
and Verity 1991). Regulated protein degrada-
tion also involves protein phosphorylation-
mediated cell signaling, and MeHg alters
intracellular protein phosphorylation.
We have demonstrated the use of a proba-
bilistic model of midbrain neurogenesis to
examine the neurodevelopmental toxicity of
MeHg. Although the model relies on some
data generated in in vitro systems, the model
allows for parameter reﬁnement as in vivo data
become available. Such models necessarily sim-
plify the processes involved in regulating CNS
ontogeny; however, we have found such mod-
els to provide a framework for synthesizing
information obtained at the biochemical, cel-
lular, and organ level. With regard to MeHg,
for example, a model can serve as a platform
for incorporating changes in biochemical
processes (e.g., Ca2+
i homeostasis), with molec-
ular effects (e.g., signal transduction, gene
expression, protein level), cellular effects (e.g.,
cell cycling), and ultimately, on the organ sys-
tem (e.g., hypoplasia). From a research per-
spective, development of such models can
serve as the basis for systematic and rational
hypothesis generation and testing. By compar-
ing predictive results from the model against
experimental observations and by linking the
biological model of effects with pharmaco-
kinetic models, we also hope to refine our
understanding of the sensitive drivers of expo-
sure and effect and thus reﬁne risk assessment.
Finally, such models can be used to examine
the relative utility of in vitro systems as models
of in vivo effects (Faustman et al. 1999).
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